- Home
- HSCS vs GTBP Comparison
HSCS vs GTBP Comparison
Compare HSCS & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSCS | GTBP |
|---|---|---|
| Founded | 2007 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 8.5M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | HSCS | GTBP |
|---|---|---|
| Price | $2.62 | $0.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.20 | N/A |
| AVG Volume (30 Days) | 13.0K | ★ 980.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,072.41 | N/A |
| Revenue Next Year | $2,700.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.01 | $0.40 |
| 52 Week High | $6.47 | $3.73 |
Technical Indicators
Market Signals| Indicator | HSCS | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 34.62 | 37.00 |
| Support Level | $2.16 | $0.41 |
| Resistance Level | $3.28 | $0.59 |
| Average True Range (ATR) | 0.11 | 0.05 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 3.64 | 17.54 |
Price Performance
Historical ComparisonAbout HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.